Advertisement

Agents and Actions

, Volume 15, Issue 5–6, pp 606–611 | Cite as

Central versus peripheral sites of antipyretic action of a non-steroidal anti-inflammatory agent, AD-1590, in rabbits

  • Hideo Nakamura
  • Yuichi Yokoyama
  • Yasuhiro Seto
  • Toshiaki Kadokawa
  • Masanao Shimizu
Immunosuppression and Inflammation Editorial

Abstracts

The site of antipyretic action of AD-1590 in the sequential process involved in the development of fever caused by bacterial pyrogen (LPS) was investigated in rabbits. AD-1590 (1μg/ml) did not inactivate both LPS and leucocytic pyrogen (LP) and did not affect the generation of LP in thein vitro test. AD-1590 (0.1 mg/kg i.v.) prevented the fever caused by LP as well as LPS, but did not prevent the fever by PGE2 (100 ng/rabbit) injected into the preoptic anterior hypothalamic (PO/AH) regions. A significant antipyretic effect of AD-1590 on LPS-fever was found when AD-1590 (4 μg/rabbit) was injected into the PO/AH regions. AD-1590 (0.4 mg/kg i.v.) did not produce antipyretic activity against 2,4-dinitrophenol-hyperthermia; the monoamine levels in the brain were not affected with AD-1590 (10 mg/kg p.o.). These results suggest that AD-1590, like acidic non-steroidal anti-inflammatory drugs, produces its antipyretic action through the central mechanisms.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    H. Nakamura, Y. Yokoyama, S. Motoyoshi, K. Ishii, C. Imazu, Y. Seto, T. Kadokawa andM. Shimizu,The pharmacological profile of 2-(8-methyl-10,11-dihydro-11-oxodibenz|bf|oxepin-2-yl)propionic acid (AD-1590), a new non-steroidal anti-inflammatory agent with potent antipyretic activity, Arzneimittel-Forsch.33, 1555–1569 (1983).Google Scholar
  2. [2]
    Y. Nagai, A. Irie, H. Nakamura, K. Hino, H. Uno andH. Nishimura,Nonsteroidal antiinflammatory agents. 1.10,11-dihydro-11-oxodibenz[b,f]oxepinacetic acids and related compounds, J. med. Chem.25, 1065–1070 (1982).CrossRefPubMedGoogle Scholar
  3. [3]
    H. Nakamura, Y. Yokoyama, Y. Seto, T. Kadokawa andM. Shimizu,AD-1590, a potent antagonist of lipopolysaccharide-induced fever in rabbits, J. Pharm. Pharmac.36, 182–186 (1984).Google Scholar
  4. [4]
    C. Rosendorff andJ.J. Mooney,Central nervous system sites of action of a purified leucocytic pyrogen, Am. J. Physiol.220, 597–603 (1971).PubMedGoogle Scholar
  5. [5]
    W.G. Clark andH.R. Cumby,The antipyretic effect of indomethacin, J. Physiol.248, 625–638 (1975).PubMedGoogle Scholar
  6. [6]
    G.H. Willies andC.J. Woolf,The site of action of corticosteroid antipyresis in the rabbit, J. Physiol.300, 1–6 (1980).PubMedGoogle Scholar
  7. [7]
    W.G. Clark andS.G. Moyer,The effects of acetaminophen and sodium salicylate on the release and activity of leucocytic pyrogen in the cat, J. Pharmac. exp. Ther.181, 183–191 (1972).Google Scholar
  8. [8]
    C.H. Sawyer, J.W. Everett andJ.D. Green,The rabbit diencephalon in stereotaxic coodinates, J. comp. Neurol.101, 801–824 (1954).CrossRefPubMedGoogle Scholar
  9. [9]
    J. Glowinski andL.L. Iversen,Regional studies of catecholamines in the rat brain — I. The disposition of [3H]norepinephrine, [3H]dopamine and [3 H]dopa in various regions of the brain, J. Neurochem.13, 655–669 (1966).PubMedGoogle Scholar
  10. [10]
    B.H.C. Westerink andJ. Korf,Rapid concurrent automatic fluorometric assay of noradrenaline, dopamine, 3,4-dihydroxy-phenylacetic acid, homovanilic acid and 3-methoxytyramine in milligram amounts of nervous tissue after isolation on Sephadex G-10, J. Neurochem.29, 697–706 (1977).Google Scholar
  11. [11]
    I.L. Bennett andP.B. Beeson,Studies in the pathogenesis of fever. II. Characterisation of fever producing substances from polymorphonuclear leucocytes and from the fluid of sterile exudates, J. exp. Med.98, 493–508 (1953).CrossRefPubMedGoogle Scholar
  12. [12]
    W.S. Feldberg andA.S. Milton, Prostaglandins and body temperature. InInflammation (Ed.J.R. Vane andS.H. Ferreira), p. 617. Springer-Verlag, Berlin, Heidelberg, New York 1978.Google Scholar
  13. [13]
    W.G. Clark,Mechanism of antipyretic action, Gen. Pharmac.10, 71–77 (1979).Google Scholar
  14. [14]
    A.S. Milton, Prostaglandins in fever and mode of action of antipyretic drugs. InPyretics and Antipyretics (Ed.A.S. Milton), p. 257. Springer-Verlag, Berlin, Heidelberg, New York 1982.Google Scholar
  15. [15]
    C. Rosendorff andC.J. Woolf, Inhibition of Fever, InAnti-inflammatory Durgs (Ed.J.R. Vane andS.H. Ferreira), p. 255. Springer-Verlag, Berlin, Heidelberg, New York 1979.Google Scholar
  16. [16]
    R.J. Flower andJ.R. Vane,Inhibition of prostaglandin synthesis in brain extracts explains the antipyretic activity of paracetamol(4-acetoaminophenol), Nature240, 410–411 (1972).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1984

Authors and Affiliations

  • Hideo Nakamura
    • 1
  • Yuichi Yokoyama
    • 1
  • Yasuhiro Seto
    • 1
  • Toshiaki Kadokawa
    • 1
  • Masanao Shimizu
    • 1
  1. 1.Department of Pharmacology, Research LaboratoriesDainippon Pharmaceutical Co., Ltd.Suita/OsakaJapan

Personalised recommendations